The medical community is facing a growing challenge in the management of male hypogonadism, as new research presented at the ENDO 2024 conference suggests that a vast majority of men receiving testosterone replacement therapy (TRT) are doing so without undergoing the full battery of diagnostic tests recommended by clinical guidelines. The study, led by Sophia Hemmrich Sinha, MD, and senior author Maria Papaleontiou, MD, an associate professor at the University of Michigan, indicates that only a small fraction of patients receive what is considered "guideline-concordant" care before being initiated on hormonal treatment. This discrepancy raises significant concerns regarding patient safety, the potential for over-diagnosis, and the long-term health implications of unnecessary hormone supplementation.
According to the findings, which were derived from a detailed retrospective chart review at Michigan Medicine, only 12% of men who were prescribed testosterone met the comprehensive criteria established by major medical organizations, such as the Endocrine Society and the American Urological Association (AUA). These criteria are designed to ensure that a patient truly suffers from clinical hypogonadism—a condition where the body does not produce enough testosterone—rather than experiencing a temporary dip in hormone levels due to acute illness, lifestyle factors, or the natural aging process.
The Scope and Methodology of the Research
The research team conducted an exhaustive analysis of 200 males assigned at birth who had at least one outpatient primary care visit at Michigan Medicine within the study period spanning 2020 to 2025. The study population had a mean age of 52.5 years, representing a demographic that is increasingly targeted by direct-to-consumer marketing for "Low T" treatments. All subjects in the sample had been diagnosed with hypogonadism and received an initial testosterone prescription during the designated timeframe.
To determine the level of guideline concordance, the researchers looked for several key diagnostic markers:
- Two separate low morning testosterone levels (total testosterone below 300 ng/dL, free testosterone below 70 pg/mL, or low bioavailable testosterone) measured between 5:00 a.m. and 10:00 a.m.
- Measurement of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) to differentiate between primary and secondary hypogonadism.
- An absence of contraindications to testosterone therapy, such as untreated obstructive sleep apnea or active prostate cancer.
The results painted a stark picture of clinical practice. While 12% of the cohort received the full recommended evaluation, the remaining 88% had incomplete laboratory workups or possessed medical conditions that should have, at the very least, prompted caution or a delay in therapy.
Identifying the Diagnostic Gaps
The most critical failure identified in the study was the lack of repeated, timed testing. Testosterone levels in men naturally fluctuate throughout the day, peaking in the early morning hours. Clinical guidelines mandate at least two morning samples to confirm a diagnosis because a single low reading can often be a false positive influenced by sleep deprivation, stress, or recent illness.
Furthermore, the study found that many patients were not screened for the underlying cause of their low testosterone. Measuring LH and FSH is essential for determining whether the issue lies in the testes (primary hypogonadism) or the pituitary gland/hypothalamus (secondary hypogonadism). Without this distinction, physicians may miss serious underlying conditions, such as pituitary tumors or systemic iron overload (hemochromatosis).
The research also highlighted a lack of baseline screening for potential side effects. While 62% of patients had their prostate-specific antigen (PSA) levels checked and 77% had a complete blood count (CBC) within the year prior to their prescription, a significant minority did not. Testosterone therapy can stimulate the production of red blood cells (erythrocytosis), which increases the risk of blood clots and stroke, and it can exacerbate subclinical prostate issues, making baseline and follow-up monitoring essential for patient safety.
Comorbidities and Contraindications
A significant portion of the study participants suffered from chronic health conditions that are known to influence testosterone levels or increase the risks associated with TRT. The data revealed that 63% of the men were obese, 52% had hypertension, 40% suffered from depression, and 28% had diabetes or arthritis.
Obesity and type 2 diabetes are frequently associated with lower total testosterone levels due to changes in sex hormone-binding globulin (SHBG). In many of these cases, weight loss and metabolic management can naturally restore testosterone levels to a normal range, potentially making hormonal intervention unnecessary.
More concerning were the findings regarding contraindications. The study found that 55% of the men had obstructive sleep apnea (OSA), a condition that can be significantly worsened by testosterone therapy, leading to severe nocturnal hypoxia. Additionally, 4% of the participants had a history of prostate cancer, and 1.5% had a PSA level greater than 4 ng/mL prior to their prescription—factors that generally serve as red flags for initiating TRT due to the hormone’s potential to stimulate the growth of prostate tissue.
Prescribing Patterns Across Specialties
The study also tracked which types of healthcare providers were initiating testosterone therapy. The distribution was as follows:
- Primary Care Physicians: 45%
- Urologists: 35.5%
- Endocrinologists: 18%
- Other Specialists: 1.5%
The fact that nearly half of the prescriptions originated in primary care suggests that these providers are on the front lines of the "Low T" phenomenon. However, it also suggests a need for better clinical decision support tools within primary care settings to ensure that guidelines are followed as strictly as they might be in a specialist’s office.
Regarding the method of delivery, topical formulations—such as gels or patches—remained the most common choice, accounting for 68.5% of the initial prescriptions. Topical treatments are often preferred for their ability to maintain steady physiological levels, but they also require strict adherence to safety protocols to prevent accidental transfer to women or children.
Chronology of Guidelines and the "Low T" Boom
To understand the implications of the Michigan Medicine study, it is necessary to look at the timeline of how testosterone therapy has evolved over the last two decades. In the early 2000s, pharmaceutical marketing began to aggressively promote the concept of "Low T," linking declining testosterone levels to common signs of aging like fatigue, low libido, and mood changes.
In response to a massive surge in prescriptions, the U.S. Food and Drug Administration (FDA) issued a safety communication in 2015, clarifying that testosterone is FDA-approved only for men who have low testosterone levels caused by specific medical conditions and not simply due to aging. The FDA also required manufacturers to add labeling regarding the possible increased risk of heart attacks and strokes.
In 2018, the Endocrine Society updated its clinical practice guidelines, emphasizing the need for rigorous diagnostic standards. These are the same standards used as the benchmark in Dr. Sinha’s research. Despite these clear directives, the Michigan study suggests that clinical practice has not yet fully aligned with these evidence-based recommendations.
Expert Analysis and Implications for Patient Care
Dr. Sophia Hemmrich Sinha noted that the findings represent a significant opportunity to improve the quality of care. "The majority of men had incomplete laboratory evaluation prior to their first testosterone prescription, and some had counter-indications to testosterone therapy," she stated. The implication is that a substantial number of men may be taking a life-long medication that they do not truly need, exposing them to risks without a guaranteed clinical benefit.
Senior author Maria Papaleontiou, MD, emphasized the need for systemic changes within healthcare networks. "Our study findings highlight opportunities to improve patient care and reduce inappropriate testosterone prescribing. Long-term, these findings can lead to quality-improvement efforts and clinical decision support tools that promote consistent, guideline-concordant testosterone prescribing," she explained.
The broader impact of these findings could lead to the development of electronic health record (EHR) alerts that flag a prescription if two morning testosterone levels or an LH/FSH test are not present in the system. Such interventions would serve as a "speed bump" for busy clinicians, ensuring that the diagnostic process is not bypassed in favor of a quick solution for patient symptoms.
Conclusion and Future Directions
The University of Michigan study serves as a critical reminder that the diagnosis of hypogonadism is a complex process that requires more than a single blood test. As the population ages and the demand for "anti-aging" interventions increases, the medical community must remain vigilant in adhering to established safety and diagnostic protocols.
Future research is expected to focus on the effectiveness of targeted interventions, such as provider education and automated clinical alerts, to see if they can successfully raise the rate of guideline-concordant care. For now, the data suggests a significant gap between what is recommended by experts and what is occurring in daily clinical practice—a gap that Dr. Sinha and her colleagues hope to bridge through continued advocacy and institutional reform. By ensuring that only those with a true clinical need receive testosterone, the medical community can better protect patient health while focusing resources on treating the underlying causes of hormonal imbalances.
